AG˹ٷ

STOCK TITAN

[8-K] Generation Bio Co. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Generation Bio Co. furnished a press release announcing its financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to this Form 8-K. The filing states the press release is being furnished rather than filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings except by specific reference. The Form 8-K itself does not include any financial figures, metrics, or narrative of the results; readers must consult Exhibit 99.1 for the actual numbers and commentary.

Generation Bio Co. ha fornito un comunicato stampa con i risultati finanziari per il trimestre chiuso al 30 giugno 2025, allegato come Exhibit 99.1 al presente Modulo 8-K. Il deposito precisa che il comunicato è stato fornito e non presentato, pertanto non è soggetto alla responsabilità ai sensi della Sezione 18 e non viene incorporato per riferimento in altri documenti, salvo specifica indicazione. Il Modulo 8-K non contiene cifre finanziarie, indicatori o una narrazione dei risultati; per i numeri e i commenti occorre consultare l'Exhibit 99.1.

Generation Bio Co. 𳾾پó un comunicado de prensa con los resultados financieros del trimestre terminado el 30 de junio de 2025, que se adjunta como Exhibit 99.1 a este Formulario 8-K. El documento indica que el comunicado se 𳾾پó y no se Գó, por lo que no está sujeto a responsabilidad conforme a la Sección 18 y no queda incorporado por referencia en otros documentos salvo mención expresa. El Formulario 8-K en sí no incluye cifras financieras, métricas ni narrativa de los resultados; los lectores deben consultar el Exhibit 99.1 para los números y comentarios reales.

Generation Bio Co.� 2025� 6� 30일로 종료� 분기� 재무 결과� 알리� 보도자료� 제공했으�, 이는 � Form 8-K� Exhibit 99.1� 첨부되어 있습니다. 제출서류에는 보도자료가 제공�(ڳܰԾ) 것이짶 젵Ӷ�(ھ) 것이 아니라고 명시되어 있어 Section 18� 따른 책임� 적용되지 않으�, 명시� 언급� 있는 경우� 제외하고 다른 제출물에 참조� 포함되지 않습니다. Form 8-K 자체에는 재무 수치, 지� 또는 결과� 대� 서술� 포함되어 있지 않으므� 실제 수치와 설명은 Exhibit 99.1� 참조해야 합니�.

Generation Bio Co. a mis à disposition un communiqué annonçant ses résultats financiers pour le trimestre clos le 30 juin 2025, lequel est joint en tant que Exhibit 99.1 à ce Form 8-K. Le dépôt précise que le communiqué est mis à disposition et non éDzé, il n'est donc pas soumis à la responsabilité prévue par la Section 18 et n'est pas incorporé par référence dans d'autres documents sauf mention expresse. Le Form 8-K lui-même ne contient aucun chiffre financier, indicateur ni exposé des résultats ; les lecteurs doivent consulter l'Exhibit 99.1 pour les chiffres et commentaires réels.

Generation Bio Co. hat eine Pressemitteilung mit den Finanzergebnissen für das Quartal zum 30. Juni 2025 bereitgestellt, die als Exhibit 99.1 diesem Form 8-K beigefügt ist. In der Einreichung wird angegeben, dass die Pressemitteilung bereitgestellt und nicht eingereicht wurde; sie unterliegt daher nicht der Haftung nach Section 18 und wird nur durch ausdrückliche Nennung in andere Einreichungen aufgenommen. Das Form 8-K selbst enthält keine Finanzzahlen, Kennzahlen oder eine Ergebnisdarstellung; für die tatsächlichen Zahlen und Kommentare ist Exhibit 99.1 heranzuziehen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine earnings disclosure furnished as an exhibit; no figures in the Form 8-K, so immediate assessment is limited.

The company has met SEC disclosure formality by furnishing a press release with quarterly results as Exhibit 99.1. Because the Form 8-K explicitly states the release is furnished and not filed, it lacks Section 18 filing liability. The absence of financial data or metrics in the Form 8-K prevents any evaluation of performance or guidance impact from this filing alone.

TL;DR: Procedural compliance confirmed; materiality cannot be judged from this filing without the attached press release.

Generation Bio followed standard practice by furnishing the press release and including the exhibit and interactive data cover page. The filing documents the administrative status of the disclosure (furnished vs. filed), which has legal implications, but it does not provide substantive financial or operational information. Determination of material impact requires review of Exhibit 99.1.

Generation Bio Co. ha fornito un comunicato stampa con i risultati finanziari per il trimestre chiuso al 30 giugno 2025, allegato come Exhibit 99.1 al presente Modulo 8-K. Il deposito precisa che il comunicato è stato fornito e non presentato, pertanto non è soggetto alla responsabilità ai sensi della Sezione 18 e non viene incorporato per riferimento in altri documenti, salvo specifica indicazione. Il Modulo 8-K non contiene cifre finanziarie, indicatori o una narrazione dei risultati; per i numeri e i commenti occorre consultare l'Exhibit 99.1.

Generation Bio Co. 𳾾پó un comunicado de prensa con los resultados financieros del trimestre terminado el 30 de junio de 2025, que se adjunta como Exhibit 99.1 a este Formulario 8-K. El documento indica que el comunicado se 𳾾پó y no se Գó, por lo que no está sujeto a responsabilidad conforme a la Sección 18 y no queda incorporado por referencia en otros documentos salvo mención expresa. El Formulario 8-K en sí no incluye cifras financieras, métricas ni narrativa de los resultados; los lectores deben consultar el Exhibit 99.1 para los números y comentarios reales.

Generation Bio Co.� 2025� 6� 30일로 종료� 분기� 재무 결과� 알리� 보도자료� 제공했으�, 이는 � Form 8-K� Exhibit 99.1� 첨부되어 있습니다. 제출서류에는 보도자료가 제공�(ڳܰԾ) 것이짶 젵Ӷ�(ھ) 것이 아니라고 명시되어 있어 Section 18� 따른 책임� 적용되지 않으�, 명시� 언급� 있는 경우� 제외하고 다른 제출물에 참조� 포함되지 않습니다. Form 8-K 자체에는 재무 수치, 지� 또는 결과� 대� 서술� 포함되어 있지 않으므� 실제 수치와 설명은 Exhibit 99.1� 참조해야 합니�.

Generation Bio Co. a mis à disposition un communiqué annonçant ses résultats financiers pour le trimestre clos le 30 juin 2025, lequel est joint en tant que Exhibit 99.1 à ce Form 8-K. Le dépôt précise que le communiqué est mis à disposition et non éDzé, il n'est donc pas soumis à la responsabilité prévue par la Section 18 et n'est pas incorporé par référence dans d'autres documents sauf mention expresse. Le Form 8-K lui-même ne contient aucun chiffre financier, indicateur ni exposé des résultats ; les lecteurs doivent consulter l'Exhibit 99.1 pour les chiffres et commentaires réels.

Generation Bio Co. hat eine Pressemitteilung mit den Finanzergebnissen für das Quartal zum 30. Juni 2025 bereitgestellt, die als Exhibit 99.1 diesem Form 8-K beigefügt ist. In der Einreichung wird angegeben, dass die Pressemitteilung bereitgestellt und nicht eingereicht wurde; sie unterliegt daher nicht der Haftung nach Section 18 und wird nur durch ausdrückliche Nennung in andere Einreichungen aufgenommen. Das Form 8-K selbst enthält keine Finanzzahlen, Kennzahlen oder eine Ergebnisdarstellung; für die tatsächlichen Zahlen und Kommentare ist Exhibit 99.1 heranzuziehen.

0001733294false00017332942025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 12, 2025

Generation Bio Co.

(Exact Name of Registrant as Specified in Charter)

Delaware

    

001-39319

    

81-4301284

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

301 Binney Street

Cambridge, MA

    

02142 

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 655-7500

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

GBIO

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Generation Bio Co. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02 on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No.

  

Description

99.1

  

Press Release Issued by Generation Bio Co. on August 12, 2025.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENERATION BIO CO.

Date: August 12, 2025

By:

/s/ Geoff McDonough

Name: Geoff McDonough, M.D.

Title: President and Chief Executive Officer

FAQ

Where are Generation Bio's (GBIO) Q2 2025 results disclosed?

The results are disclosed in a press release furnished as Exhibit 99.1 to this Form 8-K; the Form 8-K itself does not include the financial figures.

Does this Form 8-K include specific financial figures for the quarter ended June 30, 2025?

No. The Form 8-K states the press release is furnished and does not contain the financial figures or metrics within the filing itself.

Is the press release attached to the Form 8-K considered 'filed' with the SEC?

No. The filing explicitly states the press release is being furnished, not filed, and therefore is not subject to Section 18 liability.

What exhibit numbers are included with this Form 8-K?

The filing lists Exhibit 99.1 (the press release) and Exhibit 104 (the Inline XBRL cover page interactive data file).

Which quarter do the results cover in the disclosed press release?

The press release announces results for the quarter ended June 30, 2025.
Generation Bio Co.

NASDAQ:GBIO

GBIO Rankings

GBIO Latest News

GBIO Latest SEC Filings

GBIO Stock Data

27.47M
5.74M
14.31%
72.14%
1.22%
Biotechnology
Pharmaceutical Preparations
United States
CAMBRIDGE